Sister survivor: peer navigation aims to boost breast cancer aftercare
NCT ID NCT01450020
First seen Jun 24, 2026 · Last updated Aug 21, 2026 · Updated 3 times
Summary
This study tests whether peer navigators—trained breast cancer survivors—can help African-American women recently finished with breast cancer treatment better understand and stick to their follow-up care plans. About 145 women will either receive standard educational materials or also get one-on-one peer sessions. The goal is to see if this support improves quality of life and follow-up exam completion.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- peer navigation education
- What this could lead to
- If successful, this could show that peer support helps African-American breast cancer survivors better follow their follow-up care plans and feel more prepared.
- What could go wrong
- This is a small, early-stage study with 145 participants, so results may not apply to all survivors. It tests education and support, not a medical treatment, so it won't directly cure or control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 145 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2012
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * TRIAL SUBJECTS: * Patient age 18 years or older who self-identifies as African-American * In early survivorship phase, defined as being 1-12 months post completion of treatment for stage 0-3 breast cancer * Receiving health care primarily through an health maintenance organization (HMO) * Patients with metastatic cancer or a second primary cancer, because their medical characteristics (e.g. disease progression) are significantly different * Breast cancer survivors (BCS) with other major disabling medical, psychiatric, or substance abuse conditions (e.g., anxiety, depression, alcohol/tobacco problems) will be excluded * PEER NAVIGATORS: * At least 25 years of age who self-identifies as African-American * Previously participated in any type of research study * Has at least high school education * Has been diagnosed with breast cancer, currently in remission or eradicated * Belongs to a breast cancer support group * Has a valid driver's license * Owns an operational vehicle * Has access to a personal computer with internet access
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?